Could the weight loss drug that everyone is talking about also be the fountain of youth?

A new study just found that people taking semaglitead rewound the biological clock by an average of three years.

But before we start adding longevity to the drug's resume, I think we need to talk about what those numbers actually mean and who they

apply to.

Welcome to the Nutrition Diva podcast, where we take a closer look at nutrition news, research,

and trends, and answer your food and nutrition questions.

I'm your host, Monica Reinagle, and today I want to address some of the buzzy headlines that you

may have been seeing about the prescription drug semaglite. It's better known by brand names

like Ozympic and Weigovie, and its supposing anti-aging effects.

The study that sparked these headlines was a 32-week, double-blind, placebo-controlled, randomized trial.

So that is the gold standard for testing whether a treatment has real effects. But here's an important

detail right up front. The study participants were not representative of the general population

or of the vast majority of people who actually use these medications. So this study involved adults who are living with HIV.

And the trial was originally designed to see how somaglite might affect lipohypertrophy.

This is a condition that sometimes affects HIV patients, and it causes an abnormal accumulation of fat

in certain areas of the body. And somagletide was

found to be quite effective in managing this particular condition. But after the trial was over,

researchers then used some of the blood samples that they collected during the trial to do what's

called a post hoc analysis, where they go back and take another look at the data or the samples

that they've already collected to see if they can find any new or interesting patterns.

So that might mean separating out subgroups of participants, say only the women or maybe only people

over 50, and then re-analyzing the data for them separately to see if the results look any

...